Abstract: OBJECTIVE To evaluate bioavailability and whether dual nicotinate-curcumin ester is metabolized to curcumin of this nanoparticles in comparison with dual nicotinate-curcumin ester. METHODS New Zealand rabbits were selected as experiment object, blood samples were collected at different intervals after the dual nicotinate-curcumin ester nanoparticles and dual nicotinate-curcumin ester crude drug was given. The content of dual nicotinate-curcumin ester, curcumin in the blood were detected by HPLC. The AUC of transport kinetics character in vivo was calculated. The difference between nanoparticles and crude drug was compared. RESULTS The AUC was calculated by zeroth moment in the rosenblueth method, the AUC average value of crude drug was (354.835±8.660)μg·L^-1·h while the nanoparticles was (883.335±16.37) μg·L^-1·h. The value of nanoparticles was 2.486 times of crude drug. It was obvious that bioavailability could be improved by nanoparticles compared to crude drug. Curcumin in the blood were not detected. CONCLUSION The bioavailability of dual nicotinate-curcumin ester crude drug can be improved by made into nanoparticles. Dual nicotinate-curcumin ester is not metabolized to curcumin in vivo.